6533b86ffe1ef96bd12cd118

RESEARCH PRODUCT

PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)

Joerg TrojanH. SchroederJens U. MarquardtMarkus MoehlerM. A. WoernsArndt WeinmannA. KaratasJulia QuiddeAlexander SteinOliver WaidmannM. Mänz

subject

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseasePhase i studychemistry.chemical_compoundOncologychemistryInternal medicineRegorafenibmedicinebusinesshttps://doi.org/10.1016/j.annonc.2020.04.464